Human Monoclonal Antibody Combination against SARS Coronavirus: Synergy and Coverage of Escape Mutants

Background Experimental animal data show that protection against severe acute respiratory syndrome coronavirus (SARS-CoV) infection with human monoclonal antibodies (mAbs) is feasible. For an effective immune prophylaxis in humans, broad coverage of different strains of SARS-CoV and control of potential neutralization escape variants will be required. Combinations of virusneutralizing, noncompeting mAbs may have these properties.